Latest & greatest articles for fluoroquinolones

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluoroquinolones or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluoroquinolones and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluoroquinolones

1. Prevalence of fluoroquinolone-resistant (Abstract)

Prevalence of fluoroquinolone-resistant The present study was conducted to investigate the antimicrobial susceptibility profiles of Salmonella serotypes, especially fluoroquinolone-resistant strains, recovered from clinical samples in Iran. A full electronic search using related keywords was conducted in Persian and English languages in ISI Web of Knowledge, PubMed, Scopus, Google Scholar and the Scientific Information Database (SID) search engines to find papers published between 1983 and 1

2020 Pathogens and global health

2. Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis. (Abstract)

Are Fluoroquinolones or Macrolides Better for Treating Legionella Pneumonia? A Systematic Review and Meta-analysis. The Infectious Diseases Society of America recommends either a fluoroquinolone or a macrolide as a first line antibiotic treatment for Legionella pneumonia, but it is unclear which antibiotic leads to optimal clinical outcomes. We compare the effectiveness of fluoroquinolone versus macrolide monotherapy in Legionella pneumonia using a systematic review and meta-analysis.We (...) conducted a systematic search of literature in PubMed, Cochrane, Scopus and Web of Science from inception to June 1, 2019. Randomized controlled trials and observational studies comparing macrolide vs. fluoroquinolone monotherapy using clinical outcomes in patients with Legionella pneumonia were included. Twenty-one publications out of an initial 2,073 unique records met the selection criteria. Following PRISMA guidelines, two reviewers participated in data extraction. The primary outcome was mortality

2020 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

3. Fluoroquinolone Use and the Risk of Collagen-Associated Adverse Events: A Systematic Review and Meta-Analysis. (Abstract)

Fluoroquinolone Use and the Risk of Collagen-Associated Adverse Events: A Systematic Review and Meta-Analysis. It has been suggested that fluoroquinolone antibiotics increase the risk of developing collagen-associated adverse events such as aortic dissection and aortic aneurysm. These are life-threatening emergencies that need to be prevented.We performed this systematic review to clarify the association between fluoroquinolones and three collagen-associated adverse events: aortic aneurysm (...) or aortic dissection, retinal detachment, and tendon disorders.We searched PubMed, Embase, and Scopus for observational studies up to January 2019. Cohort and case-control studies were included if they reported data on the risk of collagen-related adverse events associated with fluoroquinolone exposure versus no exposure. We assessed the quality of the included studies using the Newcastle-Ottawa Scale. Effect statistics were pooled using random-effects models. Sensitivity and subgroup analyses were

2020 Drug Safety

4. Fluoroquinolones-resistant Shigella species in Iranian children: a meta-analysis. (Abstract)

Fluoroquinolones-resistant Shigella species in Iranian children: a meta-analysis. Shigella is one of the most common causes of childhood dysentery along with high rate of morbidity and mortality in both developing and developed countries. According to the World Health Organization (WHO) reports, the prevalence of fluoroquinolones-resistant Shigella species is increasing worldwide which can cause treatment failure of Shigella infections. Since there has not been any comprehensive information

2020 World journal of pediatrics : WJP

5. Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis. (Abstract)

Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis. Several fluoroquinolone antibiotics have been associated with cardiac adverse effects, leading to the withdrawal of some of these agents from the market. Cardiac side effects such as QT prolongation and torsades de pointes (TdP) have also been observed with fluoroquinolones currently on the market. In order to evaluate the cardiac risk of fluoroquinolones as a class, and the comparative risk (...) for each individual drug, we conducted a systematic review, meta-analysis, and network meta-analysis.MEDLINE, EMBASE and the Cochrane Library were searched, up to March 2018, for randomized controlled trials, cohort studies, and case-control studies that investigated the association between fluoroquinolone treatment and the risk of cardiovascular events and cardiovascular mortality. We followed the PRISMA 2009 guidelines for data selection and extraction. Outcomes were pooled using random effects

2020 Drug Safety

6. Resistance profile of clinically relevant bacterial isolates against fluoroquinolone in Ethiopia: a systematic review and meta-analysis. (Full text)

Resistance profile of clinically relevant bacterial isolates against fluoroquinolone in Ethiopia: a systematic review and meta-analysis. Fluoroquinolones are among the most frequently utilized antibacterial agents in developing countries like Ethiopia. Ciprofloxacin has become the most prescribed drug within this class and remains as one of the top three antibacterial agents prescribed in Ethiopia. However, several studies indicated that there is a gradual increase of antibacterial resistance

2020 BMC pharmacology & toxicology PubMed abstract

7. Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies. (Full text)

Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies. Our aim was to determine the relationship between the use of fluoroquinolones and the risk of aortic diseases.PubMed, EMBASE and the Web of Science were searched from inception to July 6, 2019, to identify observational studies that evaluated the risk of aortic diseases associated in users of fluoroquinolones compared with nonusers or users of other antibiotics. The primary outcome (...) was the first occurrence of aortic diseases. We used the GRADE approach to rate the strength of evidence. We used the inverse variance method random-effect model to estimate the odds ratios (ORs) with 95% CIs, and statistical heterogeneity was assessed by the I2 statistic.This meta-analysis enrolled 2,829,385 patients reported the relationship between fluoroquinolones and the risk of aortic diseases. Compared with nonusers or users of other antibiotics, users of fluoroquinolone had a significantly increased

2020 BMC cardiovascular disorders PubMed abstract

8. Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. (Abstract)

Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. Tendinopathy is a known adverse reaction associated to fluoroquinolones, but a meta-analysis was not yet published. The aim of this study was to conduct a systematic review and a meta-analysis of the scientific evidence evaluating the risk of tendon injury associated with fluoroquinolones.A literature search was conducted to identify observational studies which reported results on the risk of Achilles tendon (...) rupture (ATR), risk of Achilles tendinitis (AT), or risk of any tendon disorders (ATD). A meta-analysis was performed by pooling odds ratios (ORs) with their 95% confidence intervals (CIs).Fifteen studies were included in the meta-analysis. Treatment with fluoroquinolones was associated with an increased risk of ATR (OR 2.52 (95% CI 1.81-3.52), p < 0.001, I2 = 76.7%), an increased risk of AT (OR 3.95 (95% CI 3.11-5.01), p < 0.001, I2 = 0%), and increased risk of ATD (OR 1.98 (95% CI 1.62-2.43), p

2020 European journal of clinical pharmacology

9. Respiratory Fluoroquinolones Monotherapy vs. β-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis. (Full text)

Respiratory Fluoroquinolones Monotherapy vs. β-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis. Background: The choice of empirical antibiotic treatment for patients with community-acquired pneumonia (CAP) who are admitted to non-intensive care unit (ICU) hospital wards is complicated by the limited availability of evidence. We systematically reviewed the efficacy and safety of strategies of empirical treatment with respiratory (...) fluoroquinolone monotherapy and β-lactam with or without macrolide for non-ICU hospitalized CAP patients. Methods: We searched databases including PubMed, the Cochrane Library (Issue11, 2018), EMbase, China National Knowledge Internet (CNKI), WanFang Data, VIP, and China Biology Medicine disc (CBMdisc) to identify randomized controlled trials (RCTs) involving the comparison of respiratory fluoroquinolone monotherapy and β-lactam with or without macrolide for the non-ICU hospitalized patients with CAP up

2020 Frontiers in pharmacology PubMed abstract

10. Biological and chemical changes in fluoroquinolone-associated tendinopathies: a systematic review. (Abstract)

Biological and chemical changes in fluoroquinolone-associated tendinopathies: a systematic review. The present systematic review investigates the biological and chemical mechanisms that affect the health and structure of tendons following the use of fluoroquinolones (FQs).A total of 12 articles were included, organized, and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.Five mechanisms were identified: arrest of proliferation (...) through a decreased activity of cyclin B, CDK-1, CHK-1, and increased PK-1; decrease tenocytes migration through decreased phosphorylation of FAK; decrease type I collagen metabolism through increased MMP-2; chelate effect on ions that influence epigenetics and several enzymes; fluoroquinolones-induced ROS (radical oxygen species) production in mitochondria.There is no definite structure-damage relationship. The dose-effect relationship is unclear.Knowing and defining the damage exerted by FQs plays

2020 British medical bulletin

11. Photosensitivity induced by lomefloxacin versus other fluoroquinolones: A meta-analysis. (Abstract)

Photosensitivity induced by lomefloxacin versus other fluoroquinolones: A meta-analysis. Lomefloxacin may be more likely than other fluoroquinolones to cause photosensitivity. However, the rate of photosensitivity is variable and a meta-analysis has yet to be performed. The aim of this meta-analysis is to compare the rate of photosensitivity between outpatients who received lomefloxacin and those who received other fluoroquinolones. PubMed, EMBASE, Cochrane Library databases and trial (...) with lomefloxacin than with other fluoroquinolones (RD, 3.4%; 95% CI, 0.7%-6.2%; P-value = 0.013; I2 = 10.9%). The odds of photosensitivity was also significantly higher with lomefloxacin (Peto OR, 5.81; 95% CI, 3.34 to 10.11; P-value <0.001; I2 = 0%). This meta-analysis of RCTs found significantly higher photosensitivity with lomefloxacin compared to other fluoroquinolones. Considering this finding and given its lack of additional efficacy compared to other fluoroquinolones, lomefloxacin as a fluoroquinolone

2020 Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

12. Fluoroquinolones and the Risk of Aortic Aneurysm or Aortic Dissection: A Systematic Review and Meta-Analysis. (Full text)

Fluoroquinolones and the Risk of Aortic Aneurysm or Aortic Dissection: A Systematic Review and Meta-Analysis. We performed a systematic review and meta-analysis to explore the risk of an aortic aneurysm or aortic dissection following fluoroquinolone administration.PubMed, Cochrane library, ClinicalTrials.gov, Embase and Google Scholar were systematically reviewed for controlled studies including adult patients exposed to fluoroquinolones with a primary outcome of aortic aneurysm or aortic (...) dissection.The meta-analysis was conducted by pooling the effect estimates of four controlled observational studies (one case-control, one case-crossover and two cohort studies). Fluoroquinolone administration more than doubled the risk to develop aortic aneurysm or aortic dissection within 60 days following fluoroquinolone exposure (adjusted Relative Risk [RR] (95% confidence interval [CI]) = 2.14 (1.93 - 2.36); I2 = 15.8%). The quality of the finding was rated as moderate. The risk increase for aortic

2020 Cardiovascular & hematological agents in medicinal chemistry PubMed abstract

13. Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears

Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears - ACOG Menu ▼ Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears Page Navigation ▼ Share: Practice Advisory: FDA Warning About Fluoroquinolones and Risk of Aortic Ruptures or Tears (Replaces July 20, 2018, ACOG Practice Advisory, “New FDA Safety Warning for Fluoroquinolone (...) Antibiotics”) The U.S. Food and Drug Administration (FDA) has updated its drug safety information for oral and injectable fluoroquinolone antibiotics to include the rare but serious risk of aortic ruptures or tears in certain patients (1). The FDA advises that health care providers should not prescribe systemic fluoroquinolones for patients who have an aortic aneurysm or are at risk of an aortic aneurysm (such as patients with peripheral atherosclerotic vascular diseases, hypertension, certain genetic

2019 American College of Obstetricians and Gynecologists

14. Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: A systematic review and meta-analysis. (Abstract)

Pregnancy outcomes following quinolone and fluoroquinolone exposure during pregnancy: A systematic review and meta-analysis. To investigate whether maternal exposure to quinolones, fluoroquinolones and specifically ciprofloxacin is associated with major malformations and other adverse pregnancy outcomes.MEDLINE/PubMed, Embase and Reprotox® databases were searched. Observational studies with an exposed and control group were included.Analysis of 8 cohort and 2 case-control studies showed (...) no significant increases in rates of major malformations for quinolone (OR, 1.04; 95% CI 0.89-1.21), fluoroquinolone (RR, 0.89; 95% CI 0.70-1.14) and ciprofloxacin exposure (RR, 0.72; 95% CI 0.43-1.19). For fluoroquinolones, live birth rate was significantly decreased (RD, -0.04; 95% CI -0.08 to -0.01) whereas elective termination rate (RD, 0.04; 95% CI 0.02-0.05) was significantly increased.Quinolone, fluoroquinolone and ciprofloxacin exposure were not associated with a significant increase in major

2019 Reproductive toxicology (Elmsford, N.Y.)

15. Impact of fluoroquinolone treatment on delay of tuberculosis diagnosis: A systematic review and meta-analysis. (Full text)

Impact of fluoroquinolone treatment on delay of tuberculosis diagnosis: A systematic review and meta-analysis. Fluoroquinolones are among the most commonly used antibiotics for the treatment of respiratory infections. Because fluoroquinolones show bactericidal activity against Mycobacterium tuberculosis, there is concern that their use can delay the diagnosis of tuberculosis. We conducted a systematic review and meta-analysis to assess whether empiric treatment with fluoroquinolones delays (...) the diagnosis and treatment of tuberculosis in patients with respiratory tract infections.The primary objective was to assess the delay in days in the diagnosis and treatment of tuberculosis, among patients who received quinolones, compared to those who received non-fluoroquinolone antibiotics.We included studies of adult patients treated with fluoroquinolones prior to a confirmed diagnosis of tuberculosis. We performed a literature search of 7 databases (including PubMed, Embase and Cochrane Library

2019 Journal of clinical tuberculosis and other mycobacterial diseases PubMed abstract

17. Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. ß-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis. (Full text)

Oral Fluoroquinolone or Trimethoprim-sulfamethoxazole vs. ß-lactams as Step-Down Therapy for Enterobacteriaceae Bacteremia: Systematic Review and Meta-analysis. Using published data, we sought to compare outcomes in patients transitioned to either oral fluoroquinolones (FQ) or trimethoprim-sulfamethoxazole (TMP-SMX) versus ß-lactams (BL's) after an initial intravenous (IV) course for gram-negative rod (GNR) bacteremia.We conducted a systematic review of PubMed and EMBASE and published IDWeek

2019 Open forum infectious diseases PubMed abstract

18. Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation (Full text)

Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation Recent studies have linked fluoroquinolones (FQs) to cardiac adverse events, including aortic dissection and aneurysm. To date, whether FQs can increase the risk of aortic or mitral regurgitation has not been studied.This disproportionality analysis and case-control study examined whether FQs increase the risk of aortic and mitral regurgitation.Data from the U.S. Food and Drug Administration's adverse reporting system database

2019 EvidenceUpdates PubMed abstract

19. Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness,

Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Fluoroquinolones for the Treatment of Respiratory Tract Infections: A Review of Clinical Effectiveness, Last updated: May 6, 2019 Project Number (...) : RC1093-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of respiratory tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of respiratory tract infections? What are the evidence-based guidelines for the use of fluoroquinolones for the treatment of respiratory tract infections? Key Message Overall, 15 publications met the eligibility

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

20. Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones (...) for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: May 31, 2019 Project Number: RC1123-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of ‘other’ respiratory tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of ‘other’ respiratory tract infections

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review